ClinicalTrials.gg
CompletedNCT04239144Updated Feb 10, 2026

Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease

An interventional study of Bilateral sympathectomy and Catheter ablation in Chagas Cardiomyopathy and Ventricular Arrythmia, sponsored by University of Sao Paulo General Hospital. Completed at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by University of Sao Paulo General Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Chagas Cardiomyopathy with a site in Brazil — 2 open to participants now, 2 under way, 1 of them phase 3. Chagas Cardiomyopathy · Brazil.

Enrollment
5th of 11
45 · median 42
Started
2018
with 1 other
No phase
4 of 14
1 open now
Registered
11th of 14
by date
Lead sponsor
2 of 14
University of Sao Paulo General Hospital

Among the 14 studies in Chagas Cardiomyopathy with a site in Brazil, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2018, is one of 4 with no phase, and was the 11th registered.

Chagas Cardiomyopathy

17 studies on the registry are indexed under Chagas Cardiomyopathy; 2 are open to participants now.

Browse Chagas Cardiomyopathy studies →

Open to participants now

2 of the 14 studies in Chagas Cardiomyopathy with a site in Brazil are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 2 Chagas Cardiomyopathy studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Chagas Cardiomyopathy with a site in Brazil, or all of them as a file.
02

Study summary

Ventricular tachycardia (VT) is the main cause of sudden death in patients with structural heart diseases. The use of ICD (implantable cardio-defibrillator) could prevent sudden death, however, the occurrence of repetitive shock decreases significantly the quality of life and could increase the mortality rate. Chagas disease in our environment is the most common heart disease and often associated with the occurrence appropriate ICD therapies.

The chronic treatment of VT aims to prevent recurrences with the use of antiarrhythmic drugs and catheter ablation, but in many cases, these treatments are insufficient to control the VT. Cardiac Sympathetic Denervation by bilateral sympathectomy has been described as an alternative treatment of VT refractory to medical treatment and radiofrequency ablation, especially in patients with channelopathies. This treatment could have a role in patients with structural heart disease.

The objective of this study is to evaluate the efficacy of the bilateral sympathectomy in the reduction of ventricular tachycardia in patients with Chagas cardiomyopathy. In this pilot study, the investigators will select 45 patients with Chagas cardiomyopathy with ICD who presented at least four ICD therapies in the prior six months. These patients will be randomly assigned to three groups, 15 patients in medical therapy group, 15 in catheter ablation and 15 in bilateral sympathectomy.

Read the detailed description

OBJECTIVE

Primary

  • Evaluate the efficacy of bilateral sympathectomy in the reduction of VT episodes in patients with Chagas cardiomyopathy.

Secondary

  • To compare the efficacy of bilateral sympathectomy against VT ablation and against optimal medical therapy.
  • To evaluate the density of ventricular premature beats 24-hour Holter and monitor the events recorded by the ICD and the impact of the treatment performed.
  • To evaluate the length of the hospital stay according to the type of intervention.
  • To evaluate the rate of clinical complications according to the type of intervention.
  • To evaluate the impact of treatment on left ventricular function.

Follow up

Outcomes Assessment in six months and one year

  • Recurrence rate of appropriate therapies;
  • Density of ventricular ectopies;
  • Complication rates per type of intervention;
  • Number of in-hospital days per type of intervention;
  • Assessment of LV function;

METHODS

This is a pilot, single-centre, open-label, randomized trial in patients with Chagas disease and multiple appropriate ICD therapies. This study consists of three groups: (1) medical treatment, (2) catheter ablation and (3) bilateral sympathectomy, being included 15 patients in each group.

Inclusion Criteria:

  • Patients with Chagas Disease Cardiomyopathy having an ICD
  • At least four appropriate ICD therapies in the past six months, documented by device interrogation or medical records;
  • Use of amiodarone and beta blockers in an optimized fashion;
  • Life expectancy of more than one year
  • Conditions for following the plan of clinical follow-up of the study.

Exclusion criteria:

  • Presence of an absolute contraindication to receive any of the possible treatments of the study;
  • Pregnant Woman;
  • Less than 18 years-old;
  • Renal insufficiency with creatinine >2.5 mg/dL (221 umol/L);
  • Mobile thrombus in the left ventricle;
  • Left Ventricle Ejection fraction \< 10%;
  • Unstable angina;
  • Severe aortic stenosis
  • Primary severe mitral insufficiency;
  • New York Heart Association (NYHA) functional class IV;
  • Previous cardiac surgery or scheduled.

The patients will be recruited consecutively in the outpatient clinic of Cardiac Pacing Unit, or in outpatient clinic of Arrhythmias Clinical Unit or in the Emergency Clinical Unit.

Group 1 - Medical Treatment: patients allocated to this group will receive amiodarone reimpregnation, incremental dose of beta-blocker and if possible ICD reprogramming.

Group 2 - Catheter ablation: patients allocated to this group will undergo epicardial and endocardial catheter ablation with the use of an irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced, activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success (all VTs non-inducible); (2) partial success (clinical VT non inducible, but other morphologies still inducible) and (3) failure (clinical VT still inducible).

Group 3 - Bilateral sympathectomy - bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consists of lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion will be preserved to avoid Horner's syndrome and the electrocautery use will also be avoided for the same reason. Hemodynamic and echocardiographic behaviors will be continuously monitored during these surgical maneuvers. After the application, 10 ml of 0.25% bupivacaine solution will be injected along the site of the pleural dissection for postoperative analgesia. The lung will be reinflated under direct vision and a small tube will be inserted to remove the air through the upper incision, which will be removed at the end of the operation if possible. The two port sites will be closed primarily with absorbable stitches.

The study conformed to the principles outlined in the Declaration of Helsinki and was approved by the ethics committee and institutional review board of our hospital. All patients will provide written informed consent before randomization.

03

Conditions studied

  • Chagas Cardiomyopathy
  • Ventricular Arrythmia

Keywords

  • Ventricular Tachycardia,
  • Chagas Disease
  • Catheter Ablation
  • Bilateral Sympathectomy
  • Cardiac Sympathetic Denervation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Chagas Disease Cardiomyopathy having an ICD
  • At least four appropriate ICD therapies in the past six months, documented by device interrogation or medical records;
  • Use of amiodarone and beta blockers in an optimized fashion;
  • of more than one year
  • Conditions for following the plan of clinical follow-up of the study.

Exclusion criteria

Exclusion criteria:

  • Presence of an absolute to receive any of the possible treatments of the study;
  • Pregnant Woman;
  • Less than 18 years-old;
  • Renal insufficiency with creatinine >2.5 mg/dL (221 umol/L);
  • Mobile thrombus in the left ventricle;
  • Left Ventricle \< 10%;
  • Unstable angina;
  • Severe aortic stenosis
  • Primary severe mitral insufficiency;
  • (NYHA) functional class IV;
  • Previous cardiac surgery or scheduled.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • No intervention
    Medical therapy group

    Arm 1 - 15 patients allocated to this group will receive conventional antiarrhythmic medical treatment according the guidelines with additional impregnation of amiodarone, incremental dose of beta-blocker and if possible ICD reprograming.

  • Active comparator
    Catheter ablation

    Intervention Arm 2 -15 patients allocated to this group will undergo epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced, activation mapping will also be performed. The result of ablation will be defined as (1) complete success (all VTs non-inducible); (2) partial success (clinical VT non inducible, but other morphologies still inducible) and (3) failure (clinical VT still inducible).

    Procedure: Catheter ablation

  • Experimental
    Bilateral sympathectomy

    Interventional Arm 3 - 15 patients allocated to this group will undergo bilateral sympathectomy, which will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consists of lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion will be preserved to avoid Horner's syndrome and the electrocautery use will also be avoided for the same reason. Hemodynamic and echocardiographic behaviors will be continuously monitored during these surgical maneuvers.

    Procedure: Bilateral sympathectomy

Interventions

  • ProcedureBilateral sympathectomy

    Bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion was preserved to avoid Horner's syndrome and the electrocautery use was also avoided due to the same reason. The nerve was blocked using Ultracision device to avoid thermic lesion of the stellate ganglion. Hemodynamic and echocardiographic behaviors were continuously monitored during these surgical maneuvers.

    Also known as: Cardiac Sympathetic Denervation

  • ProcedureCatheter ablation

    Catheter ablation - patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure.

06

What researchers measure

Primary outcomes

  1. Time to Ventricular Tachycardia Recurrence

    Compare the time to the first documented Ventricular Tachycardia episode between groups

    Time frame: 12 months

  2. Burden of Ventricular Tachycardia Recurrence

    Compare the number of Ventricular Tachycardia episodes between groups in 12 months

    Time frame: 12 months

Secondary outcomes

  1. Ventricular Tachycardia Recurrence Following Sympathectomy Compared to Catheter Ablation.

    Time to first VT episode after sympathectomy compared to Catheter ablation

    Time frame: 12 months

  2. Mortality and Transplant Rate

    To compare between groups the number of patients who died or received a cardiac transplant at the end of the follow-up

    Time frame: 12 months

  3. Ventricular Ectopic Beats Density

    To evaluate the density of ventricular premature beats in the 24-hour Holter in the follow-up, for each group.

    Time frame: 12 months

  4. Length of Hospital Stay

    Compare the number of in-hospital days according to the type of intervention.

    Time frame: 12 months

  5. Rate of Complications Following Intervention

    Compare the rate of clinical complications according to the type of intervention.

    Time frame: 12 months

  6. Impact on Left Ventricular Ejection Fraction

    To evaluate the variations of the Left Ventricular Ejection Fraction in each group.

    Time frame: 12 months

  7. Autonomic Measures

    To compare the RR variability measures in the 24h-Holter between groups

    Time frame: 12 months

07

Study locations

1 site
  • Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
    São Paulo, São Paulo 05403-900, Brazil
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified data will be shared with other investigators upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: 2 years

Access criteria: Upon request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Nov 2025, 84 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2019
First posted
Jan 23, 2020
StartActual
Nov 9, 2018
Primary completionActual
Nov 18, 2025
CompletionActual
Dec 12, 2025
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04239144
Responsible party
Paulo Manuel Pêgo Fernandes (Professor, University of Sao Paulo General Hospital) — Principal investigator
First posted
Jan 23, 2020
Start date
Nov 9, 2018
Primary completion
Nov 18, 2025
Completion
Dec 12, 2025
Last update
Feb 10, 2026

Study contacts

Paulo M Pego Fernandes, MD, PhD
principal investigator · Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP)
Rodrigo M Kulchetscki, MD
principal investigator · Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP)
Maurício I Scanavacca, MD, PhD
study director · Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion